Biohaven shares fall premarket after partial FDA hold on BHV-7000

Biohaven said the Food and Drug Administration placed a partial hold on the clinical program for its BHV-7000 epilepsy drug candidate. The stock was down nearly 17% to $12.50 in premarket trading.